Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01845792|
Recruitment Status : Terminated (Low accrual)
First Posted : May 3, 2013
Results First Posted : June 4, 2018
Last Update Posted : June 4, 2018
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: Cabazitaxel with Abiraterone Acetate Drug: Cabazitaxel||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel, Compared to Cabazitaxel Alone, in Patients With Metastatic Castrate Resistant Prostate Cancer.|
|Actual Study Start Date :||July 2013|
|Actual Primary Completion Date :||February 2017|
|Actual Study Completion Date :||February 2017|
Experimental: Cabazitaxel with Abiraterone Acetate
Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.
Drug: Cabazitaxel with Abiraterone Acetate
Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
Active Comparator: Cabazitaxel Alone
Cabazitaxel administered as a single intravenous dose every 3 weeks
Cabazitaxel intravenously every 3 weeks
Other Name: Jevtana
- Progression-Free Survival [ Time Frame: 3 months ]Progression-free survival at 3 months.
- PSA Response [ Time Frame: 2 years ]Prostate specific antigen (PSA) decline by 50% or more from baseline.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 95 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Written informed consent has been obtained.
- Adults over 18 years of age.
- Histologically or cytologically proven adenocarcinoma of the prostate.
- Stage IV disease as evidenced by soft tissue, visceral and/or bony metastasis must be Response Evaluation Criteria in Solid Tumors (RECIST) evaluable on CT scan and/or bone scan
Progressive disease while receiving hormonal therapy or after surgical castration documented by at least one of the following:
- Increase in measurable disease per RECIST 1.1,
- Appearance of new lesions on bone scan consistent with progressive prostate cancer (>2 new lesions on bone scans if this is the only measure of PD),
rising PSA defined as 2 sequential increases above a previous lowest reference value.
- Each value must be obtained at least 1 week apart.
- PSA at least 2 ng/mL
- Received prior docetaxel chemotherapy
- Received prior abiraterone acetate, but not within the 3 months prior to study drug dosing.
- Testosterone level <50 ng/mL. Patients receiving Leutinizing Hormone Releasing Hormone (LHRH) agonists or antagonists must be continued to maintain castrate levels of testosterone while on study.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
Adequate hematologic function:
- platelet >100, 000/uL;
- neutrophil count of >1500 cell/mm3;
- hemoglobin >9.0 g/dL)
- Adequate renal function (Creatinine clearance > 50 mL/min)
- Adequate potassium level (> 3.5 mEq/dL)
Adequate hepatic function
- bilirubin < 1.5 X upper limit of normal (ULN),
- alanine aminotransferase (ALT) < 1.5 X ULN,
- aspartate aminotransferase (AST) < 1.5 X ULN.
- serum albumin of ≥ 3.0 g/dL.
- Controlled blood pressure, defined as blood pressure ≤ 140/90 on average (3 separate readings taken at screening visit in a relaxed clinical environment and averaged)
- Must be able to take oral medication without crushing, dissolving or chewing tablets
Willing to take abiraterone acetate on empty stomach;
(1) no food should be consumed at least two hours before and for at least one hour after the dose of abiraterone acetate is taken.
- Patients must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.
- Written authorization for use and release of health and research study information has been obtained.
- Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection during the study and for 1 week after the last dose of abiraterone acetate.
- Surgery or radiation therapy within 2 weeks, or
- Cytotoxic anti-cancer therapy within 3 weeks, or
- Non-cytotoxic anti-cancer therapy within 2 weeks, or 5 half-lives (whichever is shorter) of Study Day 1.
- Prior radiotherapy to ≥ 40% of bone marrow.
- Prior treatment with Radium 223.
- Use of an investigational therapeutic agent within 30 days.
- Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents.
- Prior treatment with cabazitaxel.
- Known chronic infection with human immunodeficiency virus (HIV).
- Known active, or symptomatic, brain metastasis.
- Blood pressure >140/90 on average (3 separate readings taken at screening visit in a relaxed clinical environment and averaged).
- History of autoimmune disorder requiring daily corticosteroid therapy of greater than prednisone 10mg daily, or its equivalent.
- Baseline peripheral edema > grade 3.
- Pre-existing diarrhea uncontrolled with supportive care;
- Prior hemorrhagic diarrhea due to ulcerative colitis, inflammatory bowel disease or other cause;
- Active, uncontrolled peptic ulcer disease even in the setting of proton-pump inhibitor or Histamine2-blocker use.
- Pre-existing peripheral neuropathy grade > 2.
- Documented hypersensitivity (CTCAE grade > 2) to any drug containing polysorbate 80.
- Have known allergies or hypersensitivity to abiraterone acetate or prednisone or their excipients.
- Contraindications to steroid use.
- Need for medications that strongly induce or inhibit cytochrome P450 3A4 (CYP3A4) or cytochrome P450 2D6 (CYP2D6) activity. (see section 7.2.3 for details)
- Serious infection requiring parenteral antibiotics within 14 days of enrollment.
- Poorly controlled diabetes (Hgb A1C >9).
- Active or symptomatic viral hepatitis or Chronic liver disease, including Child-Pugh Class B and C liver disease.
- History of pituitary or adrenal dysfunction.
Clinically significant heart disease as evidenced by:
- myocardial infarction, or
- arterial thrombotic events in the past 6 months,
- severe or unstable angina, or
- New York Heart Association Class III-IV heart disease, or
- cardiac ejection fraction measurement of <50% at baseline.
- Consumption of food or beverages containing grapefruit juice within 7 days of study drug dosing
Use of a first-generation anti-androgen such as:
- bicalutamide within 6 weeks of study drug dosing, or
- flutamide within 4 weeks of study dosing.
- Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01845792
|United States, Colorado|
|University of Colorado Cancer Center|
|Aurora, Colorado, United States, 80045|
|Principal Investigator:||Elaine Lam, MD||University of Colorado, Denver|
Documents provided by University of Colorado, Denver:
|Responsible Party:||University of Colorado, Denver|
|Other Study ID Numbers:||
NCI-2013-01356 ( Other Identifier: National Cancer Institute )
|First Posted:||May 3, 2013 Key Record Dates|
|Results First Posted:||June 4, 2018|
|Last Update Posted:||June 4, 2018|
|Last Verified:||May 2018|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
Metastatic Castrate Resistant Prostate Cancer
Genital Neoplasms, Male
Neoplasms by Site
Steroid Synthesis Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 Enzyme Inhibitors